Key result
Target-specific oral anticoagulants, including apixaban, have proven to be noninferior to vitamin K antagonists and heparins in the prevention and treatment of venous thromboembolism.
Apixaban is a target-specific oral anticoagulant that is noninferior to traditional therapies for VTE management, with specific considerations for perioperative use and special populations.
Supports apixaban use in VTE; leaves open need for larger confirmatory trials.
Venous thromboembolism (VTE) results in significant morbidity and mortality. The prevention and treatment of VTE is managed with anticoagulant therapy, historically parenteral anticoagulants such as unfractionated heparin, low molecular weight heparin, and fondaparinux, and oral vitamin K antagonists such as warfarin. In the last few years, several target-specific oral anticoagulants have been developed, including the direct thrombin inhibitor dabigatran and anti-Xa inhibitors rivaroxaban, apixaban, and edoxaban. The target-specific oral anticoagulants have proven to be noninferior to vitamin K antagonists and heparins in the prevention and treatment of VTE. This review will focus on the pharmacology, clinical trial data, and laboratory assessment of apixaban. Moreover, perioperative management, use in special populations, and management of bleeding complications in patients taking apixaban for the prevention and treatment of VTE will also be discussed.
No takes yet. Share an insight, caveat, or question.
Mandernach et al. (2015) conducted a review in Venous thromboembolism (VTE). Apixaban vs. Vitamin K antagonists and heparins was evaluated. Target-specific oral anticoagulants, including apixaban, have proven to be noninferior to vitamin K antagonists and heparins in the prevention and treatment of venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: